ArticleBiological trace element research2025
Assessment of Subacute Toxicity of Ulexite in Rats: Behavioral, Hematological, and Biochemical Insights.
Article in Biological trace element research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Boric Acid and Hyperthermia Combination: A New Cancer Therapy in The Human Hepatocellular Carcinoma and Neuroblastoma?Biological trace element research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulexite (UX), a naturally occurring borate mineral, has gained interest for its diverse industrial applications, yet its toxicological profile remains inadequately characterized. This study aimed to evaluate the subacute toxicity of UX in rats, focusing on behavioral, hematological, and biochemical parameters. Rats were administered UX via gavage at doses of 10, 30, and 300 mg/kg for 7 days. No mortality or significant signs of toxicity were observed, although body weight measurements indicated a notable reduction in the UX-treated groups compared to controls. Behavioral assessments demonstrated increased exploratory activity in the 10 and 300 mg/kg UX treated groups, suggesting low anxiety levels. Likewise, hematological analysis revealed that 30 and 300 mg/kg UX led a significant (P < 0.001) increase in hematocrit and a decrease in mean corpuscular hemoglobin concentration (P < 0.001), indicating potential changes in erythropoiesis. Additionally, serum biochemistry showed elevated aspartate aminotransferase (P < 0.05), lactate dehydrogenase (P < 0.001), and uric acid levels (P < 0.01), suggesting liver stress. Histopathological examinations indicated dose-dependent alterations, with mild hepatocellular degeneration and neuronal changes observed at the highest dose. Also, MN levels in the blood of rats exposed to 10 and 30 mg/kg UX showed no significant differences. These results suggest that UX is relatively safe at lower doses, though higher exposures may pose health risks. Further research is warranted to elucidate the mechanisms underlying UX-induced effects and to evaluate its safety for therapeutic and occupational applications.
Indexed as
Identifiers
39666170What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.